Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA BIOSENSOR MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET APPLICATION COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.1.1 THREAT OF NEW ENTRANTS – LOW TO MODERATE
4.1.2 BARGAINING POWER OF SUPPLIERS – MODERATE
4.1.3 BARGAINING POWER OF BUYERS – MODERATE TO HIGH
4.1.4 THREAT OF SUBSTITUTES - MODERATE
4.1.5 COMPETITIVE RIVALRY - HIGH
4.2 PRICING ANALYSIS
4.3 COMPANY COMPARATIVE ANALYSIS –
4.3.1 INTRODUCTION
4.3.2 CONCLUSION:-
4.4 TECHNOLOGY MATRIX
4.4.1 INTRODUCTION
4.4.2 CONCLUSION
4.5 PATENT ANALYSIS
4.6 COMPANY PRODUCT PLATFORM MATRIX
4.6.1 INTRODUCTION
4.6.2 CONCLUSION
4.7 NEW BUSINESS AND EMERGING BUSINESS'S REVENUE OPPORTUNITIES & FUTURE OUTLOOK
4.8 PENETRATION AND GROWTH POSPECT MAPPING
4.9 VALUE CHAIN ANALYSIS
4.9.1 UPSTREAM: RAW MATERIALS AND CRITICAL COMPONENTS
4.9.2 BIOSENSOR DESIGN AND MICROFABRICATION
4.9.3 INSTRUMENTATION AND PLATFORM MANUFACTURING
4.9.4 SOFTWARE, DATA INTEGRITY, AND REGULATORY ENABLEMENT
4.9.5 INTEGRATION INTO CELL & GENE THERAPY WORKFLOWS
4.9.6 END-USER ECONOMICS AND COMMERCIAL MODEL
4.9.7 BOTTOM-LINE VALUE MIGRATION
5 TARIFF & ITS ANALYSIS –
5.1 INTRODUCTION
5.2 OVERVIEW OF RELEVANT TARIFFS
5.3 TRADE POLICIES INFLUENCING THE MARKET
5.4 COST IMPACT ON STAKEHOLDERS
5.5 SUPPLY CHAIN DISRUPTIONS
5.6 STRATEGIC RESPONSE BY OEMS
5.7 CONCLUSION
6 REGULATION COVERAGE
6.1 INTRODUCTION
6.2 CGT-SPECIFIC REGULATORY CONSIDERATIONS
6.3 POST-MARKET SURVEILLANCE AND LIFECYCLE COMPLIANCE
6.4 KEY REGULATORY CHALLENGES IN THE CGT BIOSENSORS MARKET
6.5 OUTLOOK
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RAPID EXPANSION OF CELL & GENE THERAPY MANUFACTURING
7.1.2 SHIFT TOWARD REAL-TIME AND CONTINUOUS BIOPROCESS MONITORING
7.1.3 RISING FOCUS ON PERSONALIZED AND PRECISION MEDICINE
7.1.4 GROWING USE OF BIOSENSORS IN DRUG DISCOVERY AND BIOMEDICINE
7.2 RESTRAINTS
7.2.1 HIGH DEVELOPMENT AND CAPITAL COSTS
7.2.2 LIMITED SENSITIVITY AND CROSS-REACTIVITY ISSUES
7.3 OPPROTUNITIES
7.3.1 INTEGRATION WITH CLOSED AND AUTOMATED CGT MANUFACTURING PLATFORMS
7.3.2 EXPANSION OF POINT-OF-CARE AND DECENTRALIZED MONITORING IN CGT
7.3.3 AI‑ENABLED PREDICTIVE BIOPROCESS CONTROL
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY REQUIREMENTS FOR CGT MANUFACTURING TOOLS
7.4.2 LACK OF STANDARDIZATION ACROSS BIOSENSOR PLATFORMS
8 NORTH AMERICA BIOSENSOR MARKET, BY THERAPY MODALITY
8.1 OVERVIEW
8.2 NORTH AMERICA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (USD THOUSAND)
8.2.1 BIOSENSORS FOR CELL THERAPIES
8.2.2 BIOSENSORS FOR GENE THERAPIES
8.3 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.3.1 CELL VIABILITY SENSORS
8.3.2 CELL PHENOTYPE BIOSENSORS
8.3.3 CELL SURFACE MARKER DETECTION
8.4 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.4.1 NORTH AMERICA
8.4.2 EUROPE
8.4.3 ASIA-PACIFIC
8.4.4 SOUTH AMERICA
8.4.5 MIDDLE EAST AND AFRICA
8.5 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
8.5.1 VIRAL VECTOR TITER BIOSENSORS
8.5.2 CAPSID FULL/EMPTY RATIO SENSORS
8.5.3 GENOME INTEGRITY SENSORS
8.6 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
8.6.1 NORTH AMERICA
8.6.2 EUROPE
8.6.3 ASIA-PACIFIC
8.6.4 SOUTH AMERICA
8.6.5 MIDDLE EAST AND AFRICA
9 NORTH AMERICA BIOSENSOR MARKET, BY ANALYTICAL SENSOR
9.1 OVERVIEW
9.2 NORTH AMERICA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (USD THOUSAND)
9.2.1 UPSTREAM BIOPROCESS MONITORING
9.2.2 DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS
9.2.3 CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING
9.2.4 POTENCY & FUNCTIONAL ACTIVITY ASSAYS
9.3 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.3.1 CELL GROWTH & VIABILITY SENSING
9.3.2 METABOLIC PROFILING SENSORS
9.3.3 NUTRIENT CONSUMPTION SENSORS
9.3.4 WASTE METABOLITE ACCUMULATION SENSORS
9.4 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.4.1 NORTH AMERICA
9.4.2 EUROPE
9.4.3 ASIA-PACIFIC
9.4.4 SOUTH AMERICA
9.4.5 MIDDLE EAST AND AFRICA
9.5 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.5.1 CHROMATOGRAPHY PROCESS SENSORS
9.5.2 FILTRATION & CONCENTRATION MONITORING
9.5.3 VIRAL CLEARANCE VALIDATION SENSORS
9.6 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.6.1 NORTH AMERICA
9.6.2 EUROPE
9.6.3 ASIA-PACIFIC
9.6.4 SOUTH AMERICA
9.6.5 MIDDLE EAST AND AFRICA
9.7 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.7.1 PRODUCT PURITY ASSESSMENT
9.7.2 PRODUCT IDENTITY CONFIRMATION
9.7.3 STRUCTURAL INTEGRITY ANALYSIS
9.8 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.8.1 NORTH AMERICA
9.8.2 EUROPE
9.8.3 ASIA-PACIFIC
9.8.4 SOUTH AMERICA
9.8.5 MIDDLE EAST AND AFRICA
9.9 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.9.1 BINDING AFFINITY MEASUREMENTS
9.9.2 BIOACTIVITY VERIFICATION
9.1 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
9.10.1 NORTH AMERICA
9.10.2 EUROPE
9.10.3 ASIA-PACIFIC
9.10.4 SOUTH AMERICA
9.10.5 MIDDLE EAST AND AFRICA
10 NORTH AMERICA BIOSENSOR MARKET, BY REGION
10.1 NORTH AMERICA
10.1.1 U.S.
10.1.2 CANADA
10.1.3 MEXICO
11 NORTH AMERICA BIOSENSOR MARKET COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 SARTORIUS AG
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENT
13.2 AGILENT TECHNOLOGIES, INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENT
13.3 MERCK KGAA
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 BIO-RAD LABORATORIES
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENT
13.5 CYTIVA
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 AAVNERGENE
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 ABBOTT
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 ABER INSTRUMENTS LTD
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENT
13.9 ABSELION
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 CHEMOMETEC
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.11 CREATIVE-BIOLABS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 DYNAMIC-BIOSENSORS
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENT
13.13 EVROGEN
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENT
13.14 FLOWNAMICS
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENT
13.15 GENEMEDI
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENT
13.16 HAMILTON COMPANY
13.16.1 COMPANY SNAPSHOT
13.16.2 PRODUCT PORTFOLIO
13.16.3 RECENT DEVELOPMENT
13.17 HILLGENE BIOPHARMA CO., LTD.
13.17.1 COMPANY SNAPSHOT
13.17.2 PRODUCT PORTFOLIO
13.17.3 RECENT DEVELOPMENT
13.18 IST AG
13.18.1 COMPANY SNAPSHOT
13.18.2 PRODUCT PORTFOLIO
13.18.3 RECENT DEVELOPMENT
13.19 MONTANA MOLECULAR
13.19.1 COMPANY SNAPSHOT
13.19.2 PRODUCT PORTFOLIO
13.19.3 RECENT DEVELOPMENT
13.2 MYRIADE
13.20.1 COMPANY SNAPSHOT
13.20.2 7.3 PRODUCT PORTFOLIO
13.20.3 RECENT DEVELOPMENT
13.21 NANOENTEK INC.
13.21.1 COMPANY SNAPSHOT
13.21.2 REVENUE ANALYSIS
13.21.3 PRODUCT PORTFOLIO
13.21.4 RECENT DEVELOPMENT
13.22 NANOTEMPER TECHNOLOGIES
13.22.1 COMPANY SNAPSHOT
13.22.2 PRODUCT PORTFOLIO
13.22.3 RECENT DEVELOPMENT
13.23 NICOYA LIFESCIENCES INC.
13.23.1 COMPANY SNAPSHOT
13.23.2 PRODUCT PORTFOLIO
13.23.3 RECENT DEVELOPMENT
13.24 NOVA BIOMEDICAL
13.24.1 COMPANY SNAPSHOT
13.24.2 PRODUCT PORTFOLIO
13.24.3 RECENT DEVELOPMENT
13.25 PALMSENCE
13.25.1 COMPANY SNAPSHOT
13.25.2 PRODUCT PORTFOLIO
13.25.3 RECENT DEVELOPMENT
13.26 PRESENS PRECISION SENSING GMBH
13.26.1 COMPANY SNAPSHOT
13.26.2 PRODUCT PORTFOLIO
13.26.3 RECENT DEVELOPMENT
13.27 PROANALYTICS, LLC
13.27.1 COMPANY SNAPSHOT
13.27.2 PRODUCT PORTFOLIO
13.27.3 RECENT DEVELOPMENT
13.28 PROGEN
13.28.1 COMPANY SNAPSHOT
13.28.2 PRODUCT PORTFOLIO
13.28.3 RECENT DEVELOPMENT
13.29 QUANTUM BIOSCIENCES
13.29.1 COMPANY SNAPSHOT
13.29.2 PRODUCT PORTFOLIO
13.29.3 RECENT DEVELOPMENT
13.3 REFEYN LTD.
13.30.1 COMPANY SNAPSHOT
13.30.2 PRODUCT PORTFOLIO
13.30.3 RECENT DEVELOPMENT
13.31 ROCHE DIAGNOSTICS
13.31.1 COMPANY SNAPSHOT
13.31.2 REVENUE ANALYSIS
13.31.3 PRODUCT PORTFOLIO
13.31.4 RECENT DEVELOPMENT
13.32 SPHERE BIO - A FLUIDIC SCIENCES LTD BRAND.
13.32.1 COMPANY SNAPSHOT
13.32.2 PRODUCT PORTFOLIO
13.32.3 RECENT DEVELOPMENT
13.33 UNCHAINED LABS
13.33.1 COMPANY SNAPSHOT
13.33.2 PRODUCT PORTFOLIO
13.33.3 RECENT DEVELOPMENT
13.34 UNIVERSAL BIOSENSORS
13.34.1 COMPANY SNAPSHOT
13.34.2 REVENUE ANALYSIS
13.34.3 PRODUCT PORTFOLIO
13.34.4 RECENT DEVELOPMENT
13.35 YSI INC. (PART OF XYLEM INC.)
13.35.1 COMPANY SNAPSHOT
13.35.2 REVENUE ANALYSIS
13.35.3 PRODUCT PORTFOLIO
13.35.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 COMPANY COMPARATIVE ANALYSIS
TABLE 2 TECHNOLOGY MATRIX
TABLE 3 COMPANY PRODUCT PLATFORM MATRIX
TABLE 4 UPSTREAM COMPONENT COST STRUCTURE
TABLE 5 ECONOMICS OF CGT BIOSENSOR PLATFORMS
TABLE 6 SOFTWARE VALUE DRIVERS IN CGT BIOSENSORS
TABLE 7 BIOSENSOR PENETRATION BY CGT WORKFLOW STAGE
TABLE 8 TYPICAL CGT BIOSENSOR USAGE ECONOMICS
TABLE 9 COMPARATIVE REGULATORY MATRIX
TABLE 10 NORTH AMERICA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (USD THOUSAND)
TABLE 11 NORTH AMERICA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 12 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 13 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 14 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 15 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 17 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 18 NORTH AMERICA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (USD THOUSAND)
TABLE 19 NORTH AMERICA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 20 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 21 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 22 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 23 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 24 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 25 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 26 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 27 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 28 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 29 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 30 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 31 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY REGION, 2018-2033 (USD THOUSAND)
TABLE 32 NORTH AMERICA BIOSENSORS MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
TABLE 33 NORTH AMERICA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (USD THOUSAND)
TABLE 34 NORTH AMERICA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 35 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 37 NORTH AMERICA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 38 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 40 NORTH AMERICA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 41 NORTH AMERICA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (USD THOUSAND)
TABLE 42 NORTH AMERICA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 43 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 44 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 45 NORTH AMERICA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 46 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 47 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 48 NORTH AMERICA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 49 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 51 NORTH AMERICA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 52 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 53 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 54 NORTH AMERICA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 55 U.S. BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (USD THOUSAND)
TABLE 56 U.S. BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 57 U.S. BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 58 U.S. BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 59 U.S. BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 60 U.S. BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 61 U.S. BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 62 U.S. BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 63 U.S. BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (USD THOUSAND)
TABLE 64 U.S. BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 65 U.S. UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 U.S. UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 67 U.S. UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 68 U.S. DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 69 U.S. DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 70 U.S. DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 71 U.S. CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 72 U.S. CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 73 U.S. CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 74 U.S. POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 75 U.S. POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 76 U.S. POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 77 CANADA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (USD THOUSAND)
TABLE 78 CANADA BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 79 CANADA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 80 CANADA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 81 CANADA BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 82 CANADA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 83 CANADA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 84 CANADA BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 85 CANADA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (USD THOUSAND)
TABLE 86 CANADA BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 87 CANADA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 88 CANADA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 89 CANADA UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 90 CANADA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 91 CANADA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 92 CANADA DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 93 CANADA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 94 CANADA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 95 CANADA CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 96 CANADA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 97 CANADA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 98 CANADA POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 99 MEXICO BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (USD THOUSAND)
TABLE 100 MEXICO BIOSENSOR MARKET, BY THERAPY MODALITY, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 101 MEXICO BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 MEXICO BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 103 MEXICO BIOSENSORS FOR CELL THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 104 MEXICO BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 105 MEXICO BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 106 MEXICO BIOSENSORS FOR GENE THERAPIES IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 107 MEXICO BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (USD THOUSAND)
TABLE 108 MEXICO BIOSENSOR MARKET, BY ANALYTICAL SENSOR, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 109 MEXICO UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 110 MEXICO UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 111 MEXICO UPSTREAM BIOPROCESS MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 112 MEXICO DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 MEXICO DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 114 MEXICO DOWNSTREAM PROCESSING & PURIFICATION ANALYTICS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 115 MEXICO CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 MEXICO CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 117 MEXICO CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
TABLE 118 MEXICO POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 119 MEXICO POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)
TABLE 120 MEXICO POTENCY & FUNCTIONAL ACTIVITY ASSAYS IN BIOSENSOR MARKET, BY TYPE, 2018-2033 (ASP IN USD/UNITS)
List of Figure
FIGURE 1 NORTH AMERICA BIOSENSOR MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA BIOSENSOR MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BIOSENSOR MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA BIOSENSOR MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA BIOSENSOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA BIOSENSOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA BIOSENSOR MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA BIOSENSOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA BIOSENSOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA BIOSENSOR MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE NORTH AMERICA BIOSENSORS MARKET, BY THERAPY MODALITY
FIGURE 12 RAPID EXPANSION OF CELL & GENE THERAPY MANUFACTURING TO DRIVE THE NORTH AMERICA BIOSENSOR MARKET IN THE FORECAST PERIOD OF 2026 TO 2033
FIGURE 13 BIOSENSORS FOR CELL THERAPIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BIOSENSOR MARKET IN 2026 & 2033
FIGURE 14 PORTER’S FIVE FORCES
FIGURE 15 TOTAL PATENTS IN THE NORTH AMERICA BIOSENSORS MARKET
FIGURE 16 DRIVER, RESTRAINTS, OPPORTUNITIES & CHALLENGES ANALYSIS OF NORTH AMERICA BIOSENSORS MARKET
FIGURE 17 NORTH AMERICA BIOSENSOR MARKET: BY THERAPY MODALITY, 2025
FIGURE 18 NORTH AMERICA BIOSENSOR MARKET: BY THERAPY MODALITY, 2026 TO 2033 (USD MILLION)
FIGURE 19 NORTH AMERICA BIOSENSOR MARKET: BY THERAPY MODALITY, CAGR (2026- 2033)
FIGURE 20 NORTH AMERICA BIOSENSOR MARKET: BY THERAPY MODALITY, LIFELINE CURVE
FIGURE 21 NORTH AMERICA BIOSENSOR MARKET: BY ANALYTICAL SENSOR, 2025
FIGURE 22 NORTH AMERICA BIOSENSOR MARKET: BY ANALYTICAL SENSOR, 2026 TO 2033 (USD MILLION)
FIGURE 23 NORTH AMERICA BIOSENSOR MARKET: BY ANALYTICAL SENSOR, CAGR (2026- 2033)
FIGURE 24 NORTH AMERICA BIOSENSOR MARKET: BY ANALYTICAL SENSOR, LIFELINE CURVE
FIGURE 25 NORTH AMERICA BIOSENSOR MARKET: SNAPSHOT (2025)
FIGURE 26 NORTH AMERICA BIOSENSOR MARKET: COMPANY SHARE 2025 (%)
